Jiangsu Kanion Pharmaceutical Co., Ltd.

No specific pharmacological information is provided

No specific pharmacological effects mentioned

Preclinical animal experiments show that this product can enhance myocardial contractility, improve cardiac hemodynamics, improve epicardial ischemic electrocardiogram, and reduce myocardial cell acidosis; reduce coronary resistance, reduce myocardial oxygen consumption and oxygen consumption index, reduce blood pressure, slow heart rate; prolong the disappearance time of mouse electrocardiogram after tracheal clamping; prolong the survival time of mice under normal pressure and low pressure hypoxia tolerance; inhibit platelet aggregation, reduce in vitro thrombosis; improve ischemic changes in electrocardiogram caused by intravenous injection of posterior pituitary hormone; increase fasting blood glucose level in rats. In the acute toxicity test, mice were given a single oral administration of 58.8g crude drug/kg (equivalent to 223 times the clinical daily dose), and no toxic reaction was observed for 7 consecutive days; in the long-term toxicity test, rats were given oral administration of 2g crude drug/kg, 4g crude drug/kg, and 8g crude drug/kg (equivalent to 30 times, 60 times, and 120 times the clinical daily dose), and there was no obvious toxic effect for 12 consecutive weeks.

Increase the pain threshold of mice, inhibit inflammatory response, improve microcirculation, and inhibit endometrial growth

Increase pain threshold of mice, inhibit inflammatory response, improve microcirculation, and regulate hormone levels

Inhibit inflammatory response, regulate hormone levels, and improve immune function

Inhibit inflammatory response, improve microcirculation, and enhance immune function